Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β agonist treatment in a multiethnic asthma population: A genetic study

The Lancet Respiratory Medicine

Volumn 2, Issue 3, 2014, Pages 204-213

  Ortega, Victor E ^a   Hawkins, Gregory A ^a   Moore, Wendy C ^a   Hastie, Annette T ^a   Ampleford, Elizabeth J ^a   Busse, William W ^b   Castro, Mario ^c   Chardon, Domingo ^d   Erzurum, Serpil C ^e   Israel, Elliot ^f   Montealegre, Federico ^d   Wenzel, Sally E ^g   Peters, Stephen P ^a   Meyers, Deborah A ^a   Bleecker, Eugene R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^e LERNER RESEARCH INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING BETA AGONIST; UNCLASSIFIED DRUG;

ADRB2 GENE; ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; ASTHMA; CAUCASIAN; COHORT ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DRUG MEGADOSE; ETHNICITY; FEMALE; GENE INSERTION; GENETIC RISK; GENETIC VARIABILITY; HOMOZYGOTE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SYMPTOMATOLOGY;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; AFRICAN AMERICANS; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-2; UNITED STATES; YOUNG ADULT;

EID: 84895813269     PISSN: 22132600     EISSN: None     Source Type: Journal    
DOI: 10.1016/S2213-2600(13)70289-3     Document Type: Article

References (51)

1. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004, 364:1505-1512.
2. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000, 162:75-80.
3. Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010, 181:676-687.
4. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007, 370:2118-2125.
5. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 2009, 374:1754-1764.
6. Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996, 335:841-847.
7. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989, 1:917-922.
8. Pearce N, Burgess C, Crane J, Beasley R Fenoterol, asthma deaths, and asthma severity. Chest 1997, 112:1148-1150.
9. Castle W, Fuller R, Hall J, Palmer J Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993, 306:1034-1037.
10. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129:15-26.
11. FDA Drug Safety Communication: FDA requires post-market safety trials for long-acting beta-agonists (LABAs). 04/15/2011 US Food and Drug Administration, (accessed July 10, 2012). http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm.
12. Chowdhury BA, Seymour SM, Levenson MS Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011, 364:2473-2475.
13. Suissa S, Ariel A US Food and Drug Administration-mandated trials of long-acting beta-agonists safety in asthma: will we know the answer?. Chest 2013, 143:1208-1213.
14. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000, 97:10483-10488.
15. Hawkins GA, Tantisira K, Meyers DA, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006, 174:1101-1109.
16. Lester LA, Rich SS, Blumenthal MN, et al. Ethnic differences in asthma and associated phenotypes: collaborative study on the genetics of asthma. J Allergy Clin Immunol 2001, 108:357-362.
17. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010, 181:315-323.
18. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009, 179:549-558.
19. Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol 2009, 124:895-902. e1-4.
20. Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur J Epidemiol 2004, 19:411-416.
21. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007, 120(5 suppl):S94-138. National Asthma Education and Prevention Program.
22. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods 2010, 7:248-249.
23. Heinemeyer T, Wingender E, Reuter I, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998, 26:362-367.
24. Ng PC, Henikoff S Predicting deleterious amino acid substitutions. Genome Res 2001, 11:863-874.
25. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet 2011, 89:82-93.
26. Yuan HY, Chiou JJ, Tseng WH, et al. FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res 2006, 34(web server issue):W635-W641.
27. Morris AP, Zeggini E An evaluation of statistical approaches to rare variant analysis in genetic association studies. Genet Epidemiol 2010, 34:188-193.
28. Hunter DJ Gene-environment interactions in human diseases. Nat Rev Genet 2005, 6:287-298.
29. Morris AP Transethnic meta-analysis of genomewide association studies. Genet Epidemiol 2011, 35:809-822.
30. Lee S, Teslovich TM, Boehnke M, Lin X General framework for meta-analysis of rare variants in sequencing association studies. Am J Hum Genet 2013, 93:42-53.
31. Alexander DH, Novembre J, Lange K Fast model-based estimation of ancestry in unrelated individuals. Genome Res 2009, 19:1655-1664.
32. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007, 81:559-575.
33. Hall IP, Blakey JD, Al Balushi KA, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006, 368:771-779.
34. Thomsen M, Nordestgaard BG, Sethi AA, Tybjaerg-Hansen A, Dahl M Beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J 2012, 39:558-566.
35. Weir TD, Mallek N, Sandford AJ, et al. Beta2-Adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998, 158:787-791.
36. NHLBI GO exome sequencing project (ESP) Exome Variant Server, (accessed May 1, 2013). http://evs.gs.washington.edu/EVS/.
37. Wechsler ME, Castro M, Lehman E, et al. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med 2011, 184:1247-1253.
38. Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 2013, 369:351-361.
39. Walsh T, King MC Ten genes for inherited breast cancer. Cancer Cell 2007, 11:103-105.
40. Green SA, Cole G, Jacinto M, Innis M, Liggett SB A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993, 268:23116-23121.
41. Green SA, Rathz DA, Schuster AJ, Liggett SB The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001, 421:141-147.
42. Agarwal SK, Marshall GD Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 2000, 105:91-98.
43. Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583-2593.
44. Panina-Bordignon P, Mazzeo D, Lucia PD, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997, 100:1513-1519.
45. Barbato E, Penicka M, Delrue L, et al. Thr164Ile polymorphism of beta2-adrenergic receptor negatively modulates cardiac contractility: implications for prognosis in patients with idiopathic dilated cardiomyopathy. Heart 2007, 93:856-861.
46. Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001, 103:1048-1050.
47. Liggett SB, Wagoner LE, Craft LL, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998, 102:1534-1539.
48. Emorine LJ, Marullo S, Delavier-Klutchko C, Kaveri SV, Durieu-Trautmann O, Strosberg AD Structure of the gene for human beta 2-adrenergic receptor: expression and promoter characterization. Proc Natl Acad Sci USA 1987, 84:6995-6999.
49. Global strategy for asthma management and prevention Global Initiative for Asthma (GINA), (accessed May 1, 2013). http://www.ginasthma.org/local/uploads/files/GINA_Report_2012Feb13.pdf.
50. National Asthma Education and Prevention Program, expert panel report 3: guidelines for the diagnosis and management of asthma National Heart, Lung and Blood Institute, (accessed May 1, 2013). http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
51. Meyers DA, Hawkins GA, Wenzel SA, Lo K, Watt R, Bleecker ER Pharmacogenetic identification of increased responsiveness in severe asthma with anti-TNF (golimumab) therapy. J Allergy Clin Immunol 2008, 121:S798. (abstr).